Schizophrenia News and Research

Latest Schizophrenia News and Research

Scientists identify 'de novo' genetic mutations in autism spectrum disorder children

Scientists at the University of Washington (UW) Department of Genome Sciences have identified several sporadic or "de novo" genetic mutations in children with autism spectrum disorder. The researchers applied leading edge molecular biology techniques and massively parallel sequencing to simultaneously examine all of the protein coding portions of the genome, collectively called the exome.

17 May 2011

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announced results from a Phase 2 clinical trial of OPC-34712, a novel D2 dopamine partial agonist investigational product.

16 May 2011

Mylan introduces Risperidone Orally Disintegrating Tablets for schizophrenia treatment

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Risperidone Orally Disintegrating Tablets, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg, the generic version of Ortho-McNeil's Risperdal M-Tab, a treatment for schizophrenia.

13 May 2011

Two new research studies on schizophrenia

Two new research studies published in Biological Psychiatry point to progressive abnormalities in brain development that emerge as vulnerable individuals develop schizophrenia.

12 May 2011

Naurex announces completion of $18 million Series A financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of an $18 million Series A financing led by Adams Street Partners and Latterell Venture Partners.

11 May 2011

biocrea and Pfizer jointly presented details on novel PDE10 inhibitors

biocrea, a biopharmaceutical company focusing on novel treatments for disorders of the central nervous system (CNS), today reported details on the design and synthesis of novel, brain-penetrating phosphodiesterase-10 (PDE10) inhibitors developed in collaboration with Pfizer Inc. (NYSE: PFE). The data were featured in joint presentations1 with Pfizer at the recent 241st ACS National Meeting & Exposition, an event organized by the American Chemical Society (ACS).

10 May 2011

Elan Drug Technologies, Alkermes merge to form new company in Ireland

Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.

9 May 2011

Mithridion's MCD-386CR receives Orphan Drug designation from FDA for PSP treatment

Mithridion, Inc., a privately-owned clinical stage drug development company focusing on serious Central Nervous System disorders, announces that the U.S. Food and Drug Administration has awarded Orphan Drug designation for MCD-386CR, its lead drug candidate, for the treatment of Progressive Supranuclear Palsy.

9 May 2011

Summit Entertainment, Participant Media create depression awareness campaign

Inspired by Participant Media and Summit Entertainment's THE BEAVER, Participant has created a Social public Action Campaign to increase awareness about depression, teaming with three leading non-profit organizations known for effectively providing hope and help to those affected by depression and other forms of mental illness: the National Alliance on Mental Illness, To Write Love on Her Arms (TWLOHA) and the Kristin Brooks Hope Center.

7 May 2011

Researchers use virtual computer model to understand schizophrenic brains

Computer networks that can't forget fast enough can show symptoms of a kind of virtual schizophrenia, giving researchers further clues to the inner workings of schizophrenic brains, researchers at The University of Texas at Austin and Yale University have found.

6 May 2011

Novel neurotransmitter could fight against neurological diseases

A team of scientists has discovered that D-aspartic acid is a novel neurotransmitter that could potentially be used in the fight against neurological diseases such as Parkinson's and schizophrenia.

6 May 2011

Roundup: Vt. House vote on universal health care could come today; Calif. group warns of rising costs of retiree health care and pensions

The House is slated Thursday to take up a conference committee report on a bill designed to put the state on the path to universal health care by 2017 if not sooner. The bill sets up a new Green Mountain Care Board to design a system to provide health insurance to every Vermont resident.

6 May 2011

Insights into psychiatric disorders

Social deficits are common in several psychiatric disorders, including autism spectrum disorders and schizophrenia. Individuals with severe social dysfunction can experience significant difficulties with everyday functioning.

5 May 2011

Brain function variations may increase person's risk of drug abuse

One can look at drug addiction as a moral issue, a social ill, or a criminal problem. But Lynn Oswald's experience studying the neuroscience of addiction tells her that it is something else entirely: a disease of the brain.

30 Apr 2011

CTSN focuses on new prairie vole model for autism treatment

Researchers at the Center for Translational Social Neuroscience at Emory University are focusing on prairie voles as a new model to screen the effectiveness of drugs to treat autism.

29 Apr 2011

Drug subsidy issues out of PBS’ hands - almost

According to Health Minister Nicola Roxon, expensive drugs have never been automatically listed for subsidy and they can't be now when the government controlling expenses. She added that federal Labor has to balance competing priorities in health and every other department.

29 Apr 2011

Researchers confirm fish livers as good source of fatty acids

The fishing industry usually discards fish livers, but a team of researchers from the University of Almeria has confirmed that they are a good source of polyunsaturated fatty acids, which are beneficial to health. Anchovies are one of the fish whose livers contain the highest levels of these substances.

29 Apr 2011

Positive results from Shire's Vyvanse clinical trial in schizophrenia

Shire plc, the global specialty biopharmaceutical company, today announced positive results from a signal-finding study of Vyvanse(R) Capsules assessing its effect in a prospective examination of adults with negative symptom predominant schizophrenia.

28 Apr 2011

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

Alkermes, Inc. today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by The Lancet. The six-month, phase 3 trial met its primary endpoint and showed significantly greater opioid-free weeks among patients treated with VIVITROL, compared to placebo.

28 Apr 2011

Biologists determine molecular structure of GluN2D receptor subunit

Structural biologists at Cold Spring Harbor Laboratory in collaboration with colleagues at Emory University have determined the molecular structure of a key portion, or subunit, of a receptor type commonly expressed in brain cells.

27 Apr 2011